0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Week in JAMA |

This Week in JAMA FREE

JAMA. 2007;297(2):131. doi:10.1001/jama.297.2.131.
Text Size: A A A
Published online

CLOPIDOGREL AND OUTCOMES AFTER CORONARY STENTING

In an observational cohort of 4666 consecutive patients who received intracoronary stents for treatment of coronary artery disease, Eisenstein and colleaguesArticle assessed the association of clopidogrel use with long-term clinical outcomes. The authors found that patients with a drug-eluting stent who were taking clopidogrel 6 and 12 months after their initial procedure had significantly lower rates of death or myocardial infarction at a 24-month follow-up visit than patients who had discontinued clopidogrel. A similar benefit from clopidogrel was not observed among patients who had a bare-metal stent. In an editorial, KereiakesArticle discusses late thrombosis in drug-eluting stents and the implications of the study findings for patients receiving drug-eluting stents.

-TERMINAL BRAIN-TYPE NATRIURETIC PEPTIDE IN CHD

Plasma levels of the N-amino terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) provide prognostic information about patients hospitalized for decompensated heart failure, acute coronary syndromes, and other cardiac conditions, but whether NT-proBNP has prognostic utility independent of other risk factors in ambulatory patients with stable coronary heart disease (CHD) is not clear. To investigate this question, Bibbins-Domingo and colleaguesArticle examined the association of baseline NT-proBNP levels with death or cardiovascular events (myocardial infarction, stroke, or heart failure) in a prospective cohort study of patients with stable CHD. The authors found that elevated baseline levels of NT-proBNP predicted cardiovascular morbidity and mortality independent of traditional clinical and biochemical risk markers in patients with stable CHD during a mean 3.7 years of follow-up. In an editorial, KonstamArticle discusses the biology of NT-proBNP and its potential utility for predicting adverse outcomes of CHD and initiating or guiding treatment.

DRUG ADHERENCE AND LONG-TERM MORTALITY AFTER AMI

Adherence to evidence-based pharmacotherapy after acute myocardial infarction (MI) is associated with improved survival, but it is not clear whether the survival benefit is related to effects of the medication or adoption of a healthier lifestyle. Rasmussen and colleagues explored the relationship between drug adherence (statins, β-blockers, and calcium channel blockers) and mortality in a longitudinal cohort study of elderly survivors of acute MI. The authors found differential effects of drug adherence (greater for statins than β-blockers and no association for calcium channel blockers) on improved long-term survival after acute MI. Their findings support the hypothesis that the mortality benefit is more likely to be a pharmacological rather than behavioral effect.

MICROENVIRONMENTAL GENOMIC ALTERATIONS IN CANCER

Current understanding of epithelial cancers is that they are influenced by and dependent on the nonmalignant stroma or microenvironment in which they develop. Weber and colleagues assessed genomic alterations in the stroma cells of head and neck squamous cell carcinomas and correlated their findings with clinicopathological characteristics of the tumors. The authors found a high frequency of genomic alterations in the tumor stroma and identified specific alterations that correlated with tumor size, regional node metastases, and clinical stage.

MEDICAL NEWS & PERSPECTIVES

Scientists are uncovering clues to genetic and immunologic factors that play a role in systemic lupus erythematosus and are studying a therapeutic approach that may reduce disease severity and prolong remission.

CLINICIAN'S CORNER

The natural history of type 2 diabetes, reasons patients often require insulin therapy, and rationale for tight glycemic control are discussed in the case of Ms M, a 74-year-old woman with a 6-year history of diabetes and a glycated hemoglobin value of 7.4%.

ACCESS TO UNAPPROVED DRUGS

Safety, regulatory, and clinical implications of allowing terminally ill patients access to unapproved medications.

AUTHOR IN THE ROOM TELECONFERENCE

Join Dennis Black, PhD, January 17, 2007, from 2 to 3 PM eastern time to discuss the effects of continuing or stopping alendronate after 5 years. To register, go to http://www.ihi.org/AuthorintheRoom.

AUDIO COMMENTARY

Dr DeAngelis summarizes and comments on this week's issue. Go to http://jama.ama-assn.org/misc/audiocommentary.dtl.

JAMA PATIENT PAGE

For your patients: Information about insulin.

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.